Agomab Therapeutics NV opened trading on the Nasdaq Global Select Market Friday at $14.70 per share, below the $16.00 per share price set for its initial public offering. The clinical-stage biopharmaceutical company had priced 12,500,000 American Depositary Shares, or ADSs, at $16.00 apiece on Thursday. Each ADS corresponds to one common share of the company.
The offering is expected to generate approximately $200.0 million in gross proceeds to Agomab before taking into account underwriting discounts, commissions, and other offering expenses. In addition to the base allotment of ADSs, the underwriters were granted a 30-day option to purchase up to 1,875,000 additional ADSs at the initial offering price, less underwriting discounts and commissions.
Closing of the IPO is scheduled for February 9, 2026, and remains contingent on customary closing conditions. The joint book-running managers for the offering are J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen.
Agomab is a clinical-stage company concentrating on the development of novel disease-modifying therapies for immunology and inflammatory diseases, initially focusing on chronic fibrotic conditions identified as having substantial unmet medical needs. The company describes its approach as targeting established biological pathways with validated modalities, with the stated goal of improving efficacy while avoiding systemic toxicities that have constrained earlier therapeutic efforts.
The firm frames its mission around developing treatments intended to resolve fibrosis and restore organ function so that patients living with these disorders can lead fuller, healthier lives.
Context and market reception
The market debut price below the IPO level reflects early trading reception; the IPO structure, expected proceeds and the underwriters' option remain as disclosed. The scheduled closing date and customary closing conditions leave the finalization of the offering dependent on standard execution steps.
Data and terms summarized
- ADS priced: 12,500,000 at $16.00 per ADS
- Opening trade on Nasdaq: $14.70 per share
- Expected gross proceeds: $200.0 million before fees
- Underwriter option: 30 days to buy up to 1,875,000 ADSs at the initial offering price, less discounts and commissions
- IPO scheduled close: February 9, 2026, subject to customary closing conditions
- Joint book-running managers: J.P. Morgan, Morgan Stanley, Leerink Partners, Van Lanschot Kempen